Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference

Rhea-AI Summary

On April 7, 2022, Neoleukin Therapeutics (NASDAQ:NLTX) announced that its CEO, Jonathan Drachman, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference on April 14, 2022, at 12:00 p.m. Eastern. The event will be accessible via a webcast on Neoleukin's website, with an archived replay available for 30 days post-event. Neoleukin is focusing on developing next-generation immunotherapies for cancer and autoimmune conditions through advanced protein design technology, notably its lead candidate, NL-201.

SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference on Thursday, April 14, 2022 at 12:00 p.m. Eastern.

The webcast presentation can be accessed from the investors section of the Neoleukin website at http://investor.neoleukin.com/events. An archived replay will also be available on the company website for at least 30 days following the event.

About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.

Contacts:

Media
Julie Rathbun
206-769-9219
jrathbun@neoleukin.com

Investors
Solebury Trout
Alexandra Roy
617-221-9197
aroy@soleburytrout.com

FAQ

What is Neoleukin Therapeutics participating in on April 14, 2022?

Neoleukin Therapeutics will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference.

Who is the CEO of Neoleukin Therapeutics?

The CEO of Neoleukin Therapeutics is Jonathan Drachman, M.D.

Where can I access the webcast for Neoleukin's conference participation?

The webcast can be accessed from the investors section of Neoleukin's website.

What is the lead product candidate of Neoleukin Therapeutics?

Neoleukin's lead product candidate is NL-201, designed as a combined IL-2 and IL-15 agonist.

How long will the archived replay of the Neoleukin conference be available?

The archived replay will be available for at least 30 days following the event.